# A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas

> **NCT07750353** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Center, Japan** · enrollment: 35 (estimated)

## Conditions studied

- Unresectable Thymic Carcinoma

## Interventions

- **DRUG:** Sacituzumab Tirumotecan (Sac-TMT)

## Key facts

- **NCT ID:** NCT07750353
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-01
- **Primary completion:** 2029-12
- **Final completion:** 2030-06
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750353, "A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*